Rice Hall James & Associates’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-678,541
| Closed | -$2.06M | – | 257 |
|
|
2024
Q4 | $2.06M | Sell |
678,541
-51,649
| -7% | -$225K | 0.11% | 174 |
|
|
2024
Q3 | $3.79M | Buy |
730,190
+18,118
| +3% | +$90K | 0.21% | 111 |
|
|
2024
Q2 | $1.83M | Sell |
712,072
-34,067
| -5% | -$116K | 0.11% | 169 |
|
|
2024
Q1 | $3.67M | Sell |
746,139
-11,909
| -2% | -$70.5K | 0.21% | 101 |
|
|
2023
Q4 | $6.66M | Buy |
758,048
+74,111
| +11% | +$607K | 0.39% | 65 |
|
|
2023
Q3 | $7.84M | Buy |
683,937
+131,442
| +24% | +$2.53M | 0.5% | 53 |
|
|
2023
Q2 | $14M | Sell |
552,495
-256,681
| -32% | -$8M | 0.79% | 37 |
|
|
2023
Q1 | $26.1M | Sell |
809,176
-66,320
| -8% | -$2.07M | 1.48% | 14 |
|
|
2022
Q4 | $16.2M | Sell |
875,496
-21,258
| -2% | -$486K | 0.93% | 34 |
|
|
2022
Q3 | $24.2M | Sell |
896,754
-188,586
| -17% | -$3.83M | 1.4% | 16 |
|
|
2022
Q2 | $15M | Sell |
1,085,340
-26,985
| -2% | -$415K | 0.73% | 42 |
|
|
2022
Q1 | $21.7M | Sell |
1,112,325
-1,620
| -0.1% | -$24.6K | 0.86% | 37 |
|
|
2021
Q4 | $18.2M | Buy |
1,113,945
+194,185
| +21% | +$3.24M | 0.65% | 45 |
|
|
2021
Q3 | $25.6M | Sell |
919,760
-6,130
| -0.7% | -$175K | 0.95% | 33 |
|
|
2021
Q2 | $27.4M | Sell |
925,890
-180,657
| -16% | -$5.21M | 0.98% | 34 |
|
|
2021
Q1 | $30.9M | Sell |
1,106,547
-14,605
| -1% | -$404K | 1.01% | 33 |
|
|
2020
Q4 | $31.8M | Sell |
1,121,152
-8,864
| -0.8% | -$230K | 1.12% | 32 |
|
|
2020
Q3 | $28.4M | Buy |
1,130,016
+96,737
| +9% | +$2.54M | 1.14% | 30 |
|
|
2020
Q2 | $25.2M | Buy |
1,033,279
+2,998
| +0.3% | +$59.2K | 1.08% | 27 |
|
|
2020
Q1 | $15.2M | Sell |
1,030,281
-35,847
| -3% | -$741K | 0.85% | 35 |
|
|
2019
Q4 | $17.3M | Sell |
1,066,128
-12,569
| -1% | -$195K | 0.59% | 67 |
|
|
2019
Q3 | $14M | Buy |
1,078,697
+195,928
| +22% | +$2.4M | 0.5% | 81 |
|
|
2019
Q2 | $11.4M | Buy |
882,769
+765,701
| +654% | +$9.65M | 0.38% | 97 |
|
|
2019
Q1 | $1.84M | Buy |
117,068
+83,875
| +253% | +$1.45M | 0.06% | 203 |
|
|
2018
Q4 | $668K | Buy |
33,193
+8,821
| +36% | +$194K | 0.02% | 261 |
|
|
2018
Q3 | $606K | Buy |
+24,372
| New | +$663K | 0.02% | 265 |
|
Other funds holding RVNC
Rice Hall James & Associates's RVNC Position: Q1 2025 in Review
Rice Hall James & Associates sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 678,541 shares — an estimated $2.06M sold.
Rice Hall James & Associates first reported a position in RVNC in Q3 2018 and held it in 26 quarters. The position peaked at $31.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Rice Hall James & Associates reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Rice Hall James & Associates sold 678,541 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $2.06M.
- Rice Hall James & Associates first reported a position in Revance Therapeutics, Inc. in Q3 2018 and held it in 26 quarters.
- Rice Hall James & Associates's Revance Therapeutics, Inc. position peaked at $31.8M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Rice Hall James & Associates's 13F filing for Q1 2025, filed 1 May 2025.